Dr. Adrian Hernandez, executive director of the Duke Clinical Research Institute and the study's principal investigator, stated in a news release that there was no evidence of a faster time to recovery or a decrease in hospitalizations in participants who took fluticasone furoate compared to those who took a placebo.
Fluticasone furoate, another medication used to treat asthma, is ineffective for treating mild-to-moderate COVID-19, according to a recent study.
The results come from a large, countrywide trial with approximately 5,000 participants that is currently assessing the potential advantages of using already available medications to treat mild-to-moderate COVID-19.
One of three FDA-approved drugs that have been repurposed that are being evaluated against COVID-19 is fluticasone furoate. Medication used for various medical purposes but still allowed by the US Food and Drug Administration is known as repurposed medication.
An inhaled corticosteroid called fluticasone furoate is used to treat asthma, however it is not authorised to treat COVID-19.
Corticosteroids had shown promise in treating COVID-19 in outpatients, which is why this medication was investigated. The researchers emphasised that fluticasone furoate shouldn’t be used to treat COVID-19 in light of their findings.
In July 2022, the study was posted online on medRxiv, a site that posts studies before they have undergone peer review.